Clinical Trial

A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 30, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
This phase 2 study in China will evaluate the immunogenicity and safety of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.
Trial Details
NCT Number NCT07311148
Lead Sponsor Guangzhou Patronus Biotech Co., Ltd.
Conditions Herpes Zoster (HZ), Shingles, VZV, Recombinant Zoster Vaccine
Enrollment 840 participants
Start Date 2025-10-23
Primary Completion 2026-01 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-30